CASI Pharmaceuticals Inc.: Commercially launched EVOMELA® (melphalan for injection: multiple myeloma) on Aug 8, 2019; NMPA review in progress for ZEVALIN® and MARQIBO® (in-licensed from Spectrum). Recently (2Q19) acq'd exclusive WW rights to commercialize anti-CD19 T-cell therapy (CNCT19) in China as well as exclusive WW rights to novel anti-CD38 mAb (CID-103). Acq'd 25 US FDA-approved ANDAS from Sandoz in Jan 2018.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Disease Space
Oncology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.